Skip to main content

Table 1 Patients characteristics

From: A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

   All
(N = 83) (%)
No ascites
(N = 43) (%)
Small to moderate ascites
(N = 26) (%)
Massive ascites
(N = 14) (%)
Age Median (range) 67 (23–83) 68 (48–78) 64.5 (23–83) 67.5 (32–81)
Gender Male* 60 (72) 37 (86) 15 (58) 8 (57)
ECOG PS 0* 48 (58) 28 (65) 18 (69) 2 (14)
1 25 (30) 13 (30) 5 (19) 7 (50)
2* 10 (12) 2 (5) 3 (12) 5 (36)
Histological Type Diffuse 47 (57) 20 (46) 17 (65) 10 (71)
Intestinal 36 (43) 23 (54) 9 (35) 4 (29)
Number of previous CTX 1 59 (71) 29 (67) 18 (69) 12 (86)
≥2 24 (29) 14 (33) 8 (31) 2 (14)
Gastrectomy Yes 31 (37) 18 (42) 7 (27) 6 (43)
Target lesion Yes 45 (54) 28 (65) 12 (46) 5 (36)
Site of metastasis Lymph node 56 (67) 34 (79) 15 (58) 7 (50)
Liver 22 (27) 13 (30) 7 (27) 2 (14)
Peritoneal 49 (59) 11 (26) 24 (92) 14 (100)
Ovary* 10 (12) 1 (2) 5 (19) 4 (29)
Number of metastases 1–2* 70 (84) 39 (91) 19 (73) 12 (86)
≥ 3 13 (16) 4 (9) 7 (27) 2 (14)
  1. CTX chemotherapy
  2. *p < 0.05